Medtronic plc (NYSE: MDT) today announced that the Resolute Onyx(TM) Drug-Eluting Stent (DES) met its primary endpoint of Target Lesion Failure (TLF) at one year for the treatment of coronary artery disease in extra-small vessels. Results from the RESOLUTE ONYX 2.0 mm Clinical Study were presented today as a Hot Line/Late-Breaking Trial Session at the 2017 EuroPCR Annual Meeting and simultaneously published in the Journal of the American College of Cardiology (JACC): Cardiovascular Intervention.

Boston Scientific’s transcatheter aortic valve implantation (TAVI) technology, the LOTUS Valve System, shows superiority to a similar platform made by a competitor in a new clinical trial.

MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- Boston Scientific (NYSE: BSX) today announced positive safety and efficacy rates of the WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device from the EWOLUTION registry presented during a late-breaking clinical trial session at Heart Rhythm 2017, the Heart Rhythm Society's 38th Annual Scientific Sessions in Chicago. Data confirmed that the WATCHMAN device had a high implant success rate and was effective in stroke reduction for patients with non-valvular atrial fibrillation (AF), including those patients deemed unsuitable for oral anticoagulation.

Professor William Wijns, co-director of EuroPCR and chairman of PCR, has joined NUI Galway as a professor of medical devices. He will head the $5 million research project to develop wearable sensors for patients at high risk of heart attacks.

Thoratec Corporation, a world leader in mechanical circulatory support therapies to save, support and restore failing hearts, announced that the FDA has granted conditional approval for a U.S. IDE clinical trial to investigate use of the HeartMate PHP acute catheter-based heart pump in patients undergoing a high-risk percutaneous coronary intervention.

Are Riata concerns a thing of the past and transcatheter aortic valve replacement (TAVR) for almost anyone with severe aortic stenosis the way of the future? Presentations at recent cardiology conferences addressed those questions.

Edwards Lifesciences put enrollment into a program using its FORTIS transcatheter valve replacement therapy on hold, announcing that it wants to investigate reports of valve thrombus.

Transcatheter aortic valve replacement (TAVR) continued to hold its own against surgery in low-risk patients with severe aortic stenosis, based on two-year results presented May 19 at EuroPCR in Paris.